In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization

Drug Metabolism and Disposition

Volumn 29, Issue 5, 2001, Pages 638-644

  Yergey, James A ^a,b   Trimble, Laird A ^a   Silva, José ^a   Chauret, Nathalie ^a   Li, Chun ^a   Therien, Michel ^a   Grimm, Erich ^a   Nicoll Griffith, Deborah A ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; CYCLOOXYGENASE 2 INHIBITOR; GLUCURONIDE; GLUTATHIONE;

ANIMAL CELL; AROMATIZATION; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FURANS; GLUTATHIONE; ISOENZYMES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICROSOMES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0035041101     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Characterization of carbamazepine metabolism in a mouse model of carbamazepine teratogenicity
2. Microsomal metabolism of the 5-lipoxygenase inhibitors L-746,530 and L-739,010 to reactive intermediates that covalently bind to protein: The role of the 6,8-dloxabicyclo[3.2.1]octanyl moiety
3. Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in rabbit, mouse and human: Identification of fluorine NIH shift metabolites using NMR and tandem MS
4. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
5. Studies of themicrosomal formation of arylating metabolites of acetaminophen and phenacetin
6. Specific inhibition ofcyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
7. Cyclooxygenase-2 specificity and its clinical implications
8. Integrated application of capillary HPLC/continuous-flow liquid secondary ion mass spectrometry to discovery stage metabolism studies
9. Partial purification of cytochromes P-450 and P448 from rat liver microsomes
10. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man
11. Evidence for the involvement of N-acetyl-p-quinoneimine in acetaminophen metabolism
12. Acetaminophen-induced hepatic injury: Protective role of glutathione in man and rationale for therapy
13. Comparative electron impact, chemical ionization and field desorption mass spectra of some thioether metabolites of acetaminophen
14. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from β-naphthoflavone treated rodents (P-4501A1)
15. Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitor
16. Biotransformation of CI-937 in primary cultures of rat hepatocytes: Formation of glutathione conjugates
17. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
18. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans
19. Refinement of an in vitro model for cytochrome P450 induction
20. In vitro thiomethylation, studies with fluniezapine